

Serena Bugatti

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4979427/serena-bugatti-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

72 papers	1,590 citations	24 h-index	39 g-index
99 ext. papers	1,994 ext. citations	5.6 avg, IF	4.49 L-index

#	Paper	IF	Citations
72	The novel cytokine interleukin-36 β s expressed in psoriatic and rheumatoid arthritis synovium. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1569-74	2.4	116
71	Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. <i>Arthritis Research</i> , 2004 , 6, R264-72		112
70	B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers. <i>BioMed Research International</i> , 2014 , 2014, 681678	3	92
69	Involvement of subchondral bone marrow in rheumatoid arthritis: lymphoid neogenesis and in situ relationship to subchondral bone marrow osteoclast recruitment. <i>Arthritis and Rheumatism</i> , 2005 , 52, 3448-59		83
68	CCL21 relationship with lymphoid neogenesis and lymphatic vascular system in chronically inflamed synovium. <i>Arthritis Research</i> , 2005 , 7, P139		78
67	CCL21 expression pattern of human secondary lymphoid organ stroma is conserved in inflammatory lesions with lymphoid neogenesis. <i>American Journal of Pathology</i> , 2007 , 171, 1549-62	5.8	76
66	Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. <i>RMD Open</i> , 2015 , 1, e000057	5.7	68
65	Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016 , 18, 226	5.7	68
64	Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases. <i>Immunology Letters</i> , 2012 , 145, 62-7	4.1	68
63	B cells in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2007 , 7, 137-42	13.6	65
62	High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease. <i>Rheumatology</i> , 2014 , 53, 1886-95	3.9	48
61	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. <i>Lancet, The</i> , 2021 , 397, 305-317	40	42
60	Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs. <i>Arthritis Research and Therapy</i> , 2012 , 14, R34	5.7	40
59	The Clinical Value of Autoantibodies in Rheumatoid Arthritis. <i>Frontiers in Medicine</i> , 2018 , 5, 339	4.9	39
58	Synovial tissue heterogeneity and peripheral blood biomarkers. <i>Current Rheumatology Reports</i> , 2011 , 13, 440-8	4.9	33
57	Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. <i>Annals of the New York Academy of Sciences</i> , 2010 , 1193, 139-45	6.5	32
56	Subclinical remodelling of draining lymph node structure in early and established rheumatoid arthritis assessed by power Doppler ultrasonography. <i>Rheumatology</i> , 2011 , 50, 1395-400	3.9	31

55	Inflammatory lesions in the bone marrow of rheumatoid arthritis patients: a morphological perspective. <i>Arthritis Research and Therapy</i> , 2012 , 14, 229	5.7	30
54	Long term treatment of rheumatoid arthritis with rituximab. <i>Autoimmunity Reviews</i> , 2009 , 8, 591-4	13.6	29
53	Long-term safety of abatacept in patients with rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2013 , 12, 1115-7	13.6	28
52	Use of ultrasound-guided small joint biopsy to evaluate the histopathologic response to rheumatoid arthritis therapy: recommendations for application to clinical trials. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2601-10	9.5	26
51	The draining lymph node in rheumatoid arthritis: current concepts and research perspectives. <i>BioMed Research International</i> , 2015 , 2015, 420251	3	25
50	Autoantibodies to heterogeneous nuclear ribonucleoproteins. <i>Autoimmunity</i> , 2005 , 38, 25-32	3	25
49	Early treatment in early undifferentiated arthritis. <i>Autoimmunity Reviews</i> , 2012 , 11, 589-92	13.6	24
48	Transient monoarthritis and psoriatic skin lesions following COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	24
47	Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. <i>Clinical and Experimental Rheumatology</i> , 2011 , 29, S7-14	2.2	23
46	A Multicenter Retrospective Analysis Evaluating Performance of Synovial Biopsy Techniques in Patients With Inflammatory Arthritis: Arthroscopic Versus Ultrasound-Guided Versus Blind Needle Biopsy. <i>Arthritis and Rheumatology</i> , 2018 , 70, 702-710	9.5	22
45	Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter--Determining Validation Requirements. <i>Journal of Rheumatology</i> , 2016 , 43, 208-13	4.1	22
44	Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: could it be the first step of the treatment?. <i>Autoimmunity Reviews</i> , 2014 , 13, 49-53	13.6	22
43	Assessment of synovitis to predict bone erosions in rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012 , 4, 235-44	3.8	22
42	Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1635-1638	2.4	21
41	Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs. <i>BioMed Research International</i> , 2014 , 2014, 831603	3	18
40	B cells in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2007 , 6, 482-7	13.6	18
39	Ultrasonographic and MRI characterisation of the palindromic phase of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 625-6	2.4	16
38	B cell autoimmunity and bone damage in rheumatoid arthritis. <i>Reumatismo</i> , 2016 , 68, 117-125	1.1	14

37	Rheumatoid arthritis in beta-thalassemic trait: clinical, serologic and immunogenetic profile. <i>Joint Bone Spine</i> , 2004 , 71, 117-20	2.9	8
36	Established rheumatoid arthritis. The pathogenic aspects. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019 , 33, 101478	5.3	8
35	What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated Peptide antibodies?. <i>Journal of Rheumatology</i> , 2008 , 35, 1903-5	4.1	8
34	Correspondence on EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e156	2.4	7
33	In early inflammatory polyarthritis more intensive management according to the 2010 ACR/EULAR criteria leads to higher rates of clinical remission: comparison of two cohorts treated according to different treat-to-target protocols. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 401-405	2.2	7
32	Clinical, Imaging, and Pathological Suppression of Synovitis in Rheumatoid Arthritis: Is the Disease Curable?. <i>Frontiers in Medicine</i> , 2018 , 5, 140	4.9	6
31	Baseline serum concentrations of TRAIL in early rheumatoid arthritis: relationship with response to disease-modifying antirheumatic drugs. <i>Journal of Rheumatology</i> , 2010 , 37, 1461-6	4.1	6
30	Power Doppler ultrasonographic assessment of the joint-draining lymph node complex in rheumatoid arthritis: a prospective, proof-of-concept study on treatment with tumor necrosis factor inhibitors. <i>Arthritis Research and Therapy</i> , 2016 , 18, 242	5.7	6
29	Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	4
28	Histopathology of the synovial tissue: perspectives for biomarker development in chronic inflammatory arthritides. <i>Reumatismo</i> , 2018 , 70, 121-132	1.1	4
27	The Genetic, Environmental, and Immunopathological Complexity of Autoantibody-Negative Rheumatoid Arthritis. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
26	B cell distribution and activation-induced cytidine deaminase expression in rheumatoid synovitis: clinical and bio-molecular correlates. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, A55-A55	2.4	2
25	THU0058 B CELL SYNOVITIS AND CLINICAL PHENOTYPES IN RHEUMATOID ARTHRITIS AT DIFFERENT DISEASE STAGES 2019 ,		2
24	Clinical Applications of Synovial Biopsy. <i>Frontiers in Medicine</i> , 2019 , 6, 102	4.9	1
23	SAT0087 Serum Levels of CXCL13 Refine The Predictive Ability of Autoantibodies To Identify Unstable Remission in Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 696.3-696	2.4	1
22	A5.14 Serum CXCL13 is a non-invasive synovitis marker holding non-redundant information compared with acute phase reactants and autoantibodies in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, A46.3-A47	2.4	1
21	THU0546 Serum CXCL13 as A Biomarker of Disease Activity and Severity in IN Rheumatoid Arthritis. Comparison with Acute Phase Reactants and the Autoantibody Profile. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 371.2-371	2.4	1
20	Challenges in the diagnosis of early rheumatoid arthritis in times of COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1242-1243	2.4	1

19	In Patients with Early Peripheral Psoriatic Arthritis Baseline C-Reactive Protein, Pain and Ultrasound-Detected Synovitis Predict Subsequent Treatment with ts/bDMARDs. A Retrospective Analysis. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
18	Impact of Anti-Citrullinated Protein Antibodies on Progressive Systemic Bone Mineral Density Loss in Patients With Early Rheumatoid Arthritis After Two Years of Treat-to-Target. <i>Frontiers in Immunology</i> , 2021 , 12, 701922	8.4	1
17	Limiting factors to Boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759720X211011826	3.8	1
16	THU0234 Short-Term Clinical Outcome and Ultrasonographic-Synovitis Dynamics in Rheumatoid Arthritis Patients in Dmards-Induced SDAI Remission under Drug-Free Conditions. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 263.1-263	2.4	0
15	Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry. <i>Clinical Rheumatology</i> , 2021 , 40, 4039-4047	3.9	0
14	Insights Into the Concept of Rheumatoid Arthritis Flare.. <i>Frontiers in Medicine</i> , 2022 , 9, 852220	4.9	0
13	AB0270 Worsening of Diagnostic Delay in Early Arthritis during The Last 10 Years: A Single Center Experience. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 992.1-992	2.4	
12	A1.13 Ultrasound-guided assesement of axillary lymph nodes in rheumatoid arthritis: cross-sectional and prospective clinico-pathologic significance. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, A6.1-A6	2.4	
11	FRI0067 Anti-Citrullinated Protein Antibodies and Generalised Bone Loss in Patients with Early Rheumatoid Arthritis: A Causal Relationship?. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 405.3-406	2.4	
10	A8.29 Outcome and predictors of relapse in early rheumatoid arthritis patients achieving DMARDs-induced stable remission during drug-free follow-up. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, A93.2-A93	2.4	
9	THU0120 Prognostic Significance of Residual Autoimmune/Inflammatory Activity for Disease Relapse Upon Dmard Suspension in Patients with Early Rheumatoid Arthritis in Sustained Remission After DAS-Driven Therapy. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 237.3-237	2.4	
8	AB0263 Clinical Onset and Squeezing Test Positivity Influence the Probability to Achieve Clinical Remission at 12 Months in Patients with Early Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 979.2-980	2.4	
7	FRI0041 Usefulness of the Classification Criteria for RA as Guidance for Treatment Selection in an Early Arthritis Cohort: 2010 Criteria Lead to Higher Rates of Clinical Remission. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 396.1-396	2.4	
6	Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, A12.3-A13	2.4	
5	SAT0114 Synovial B cell infiltration in relationship to diagnosis and outcome in early arthritis according to the 2010 ACR/EULAR classification criteria. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 508.3-509	2.4	
4	A10.17 Interleukin-36̢s Expressed by Synovial Plasma Cells and Induces Cytokine Production in Human Fibroblasts. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A78.1-A78	2.4	
3	Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus. <i>International Journal of Molecular Medicine</i> , 2005 , 15, 661	4.4	
2	A5.13 Power-doppler ultrasound assessment of the joint-draining lymph node complex in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, A46.2-A46	2.4	

1

SAT0540 Power Doppler Ultrasound Imaging of The Joint-Draining Lymph Node Complex in Rheumatoid Arthritis. *Annals of the Rheumatic Diseases*, **2016**, 75, 864.3-865

2.4